Posluma
Posluma (flotufolastat F 18) is an radiopharmaceutical imaging agent that helps providers see areas of prostate cancer on a specific test known as a prostate-specific membrane antigen – positron emission tomography (PSMA-PET) scan. It’s for people with prostate cancer that might have come back after initial treatment (recurrent) or spread (metastasized) to other parts of the body. It’s given as an infusion through the vein before the PET scan. Side effects include diarrhea, injection site pain, and a rise in blood pressure.
What is Posluma (flotufolastat F 18)?
What is Posluma (flotufolastat F 18) used for?
- Diagnose suspected advanced prostate cancer, during a PSMA-PET scan
How Posluma (flotufolastat F 18) works
Posluma (flotufolastat F 18) is a radiopharmaceutical. It attaches to a particular protein found on the surface of certain cancer cells called prostate-specific membrane antigen (PSMA). Once attached, the radioactive portion of Posluma (flotufolastat F 18) lights up the areas with prostate cancer on a certain type of scan called a PSMA PET scan.
Drug facts
| Common Brands | Posluma |
|---|---|
| Drug Class | Radiopharmaceutical |
| Controlled Substance Classification | Not a controlled medication |
| Generic Status | No lower-cost generic available |
| Availability | Prescription only |